Drug Trial Radar · NCT02644551
The Efficacy of CELEXT07 in the Treatment of Toenail Onychomycosis
Last checked: Nov 20, 2026Latest source record: Apr 26, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
120
Planned (sponsor's estimate)
Start
Nov 2016
Primary completion
May 2018
Study completion Sep 2018
Sponsor
- Lead sponsor
- 9305-9954 Quebec IncIndustry
- Sponsor type
- Industry
- First posted
- Jan 1, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This will be an interventional safety and efficacy study of CELENT07 when used as a topical treatment of onychomycosis in the toenails (tinea unguium) of adults 18 years and older. This is randomized, double-blind, parallel design, placebo and active controlled study in patients with mild to moderate toenail distal lateral subungual onychomycosis (DLSO) (n=120). Subjects will be randomized (1:1:1) to receive CELENXT07, placebo of CELENXT07 or PENLAC®, daily for 52 weeks. Efficacy assessments will include complete cure, mycologic cure and clinical efficacy and safety and tolerability.
Conditions
- Onychomycosis
Interventions
CELEXT07Drug
PenlacDrug
vehicle solutionOther
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy Assessed by Complete Cure Rate at the End of Study (Week 52) After Treating for 52 WeeksTime frame: week 52
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinique podiatrique de Montréal
Montreal, Quebec, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.